Publication
The Development of a Dimroth Rearrangement Route to AZD8931
Recently, the aminoquinazoline motif has been highly prevalent in anticancer pharmaceutical compounds. Synthetic methods are required to make this structure on a multikilo scale and in high purity.
Unit Operation: Reaction
Objective: Design
Company: AstraZeneca
Source: Org. Process Res. Dev., 2017, 21 (3), pp 336–345
Authors: Kay Boardman (AstraZeneca), Oliver Cunningham (AstraZeneca), Matthew Evans (AstraZeneca), William R. F. Goundry (AstraZeneca), Martin F. Jones (AstraZeneca), Kirsty Millard (AstraZeneca), Raquel Rozada-Sanchez (AstraZeneca), Yvonne Sawyer (AstraZeneca), Paul Siedlecki (AstraZeneca), Brian Whitlock (AstraZeneca)
Publish Date: 01-Feb-2017
Copyright © 2018 Scale-up Systems Ltd. | DynoChem Software and Development Services for the Pharma Industry | Privacy | Cookies | Contact